Allakos Inc. (ALLK)
NASDAQ: ALLK · Real-Time Price · USD
0.3265
-0.0001 (-0.03%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Company Description
Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jul 19, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Robert Alexander |
Contact Details
Address: 825 Industrial Road, Suite 500 San Carlos, California 94070 United States | |
| Phone | 650 597 5002 |
| Website | allakos.com |
Stock Details
| Ticker Symbol | ALLK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001564824 |
| CUSIP Number | 01671P100 |
| ISIN Number | US01671P1003 |
| Employer ID | 45-4798831 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Alexander Ph.D. | Chief Executive Officer and Director |
| Dr. Adam L. Tomasi Ph.D. | President |
| H. Baird Radford III | Chief Financial Officer |
| Alan Chang | Director of Medical Affairs and Data Analytics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | 10-K/A | [Amend] Annual report |
| Apr 17, 2025 | SCHEDULE 13D/A | Filing |
| Apr 15, 2025 | SC 14D9 | Filing |
| Apr 15, 2025 | SC TO-T | Filing |
| Apr 9, 2025 | SCHEDULE 13G | Filing |
| Apr 3, 2025 | SCHEDULE 13D/A | Filing |
| Apr 2, 2025 | SC14D9C | Filing |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 12, 2025 | 10-K | Annual Report |